文献速递牙体牙髓病

炎症性肠病患者接受抗肿瘤坏死因子α治疗后的根尖周炎愈合情况

Healing of Apical Periodontitis in Patients with Inflammatory Bowel Diseases and under Anti-tumor Necrosis Factor Alpha Therapy.
PubMed 文献 · J Endod · 2018-11-01

本研究评估了接受抗肿瘤坏死因子α生物制剂的炎症性肠病患者根尖周炎经非手术根管治疗后的愈合情况,并与无系统性疾病对照组比较。结果显示,生物制剂组所有牙齿均愈合,对照组愈合率为81%,差异无统计学意义,但生物制剂组愈合速度更快,且无并发症。

要点

  • 炎症性肠病患者接受生物制剂治疗时根尖周炎愈合无并发症。
  • 生物制剂组愈合速度可能快于对照组,但差异无统计学意义。
  • 研究结果提示生物制剂可能对根尖周炎治疗有辅助作用。

核心结论

  • 接受生物制剂治疗的炎症性肠病患者根尖周炎根管治疗无并发症,且愈合速度可能更快。

主要发现

  • 生物制剂组所有牙齿均愈合,对照组愈合率为81%(P = .108)。
  • 生物制剂组初始愈合在3个月可观察到,对照组在6个月(P = .174)。
  • 总体愈合时间在生物制剂组为6个月,对照组为10.5个月(P = .106)。
  • 生物制剂组在任何时间点愈合概率均更高(P < .05)。
  • 两组根尖周指数下降程度相似(P = .291),但生物制剂组在3个月随访时下降更显著(P < .05)。

关键数值与推荐

  • 使用两种生物制剂的患者愈合趋势相似(P = .628)。

临床怎么用

  • 对于接受生物制剂治疗的炎症性肠病患者,根尖周炎可进行常规根管治疗,无需担心并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We evaluated healing after nonsurgical primary/secondary endodontic treatment of apical periodontitis (AP) in patients with inflammatory bowel diseases (IBDs) treated with anti-tumor necrosis factor alpha biologic medications (BMs). METHODS: Nineteen patients with 22 teeth affected by AP from the gastroenterology unit of the hospital with IBDs under treatment with BMs formed the study group (the IBD group). Fourteen patients with 22 teeth with AP, matched by age and sex, without systemic diseases and not taking medications formed the control group. Teeth underwent primary or secondary root canal treatments and clinical and radiographic follow-up every 3 months for 24 months. The periapical index score was recorded, and 2 trained and calibrated endodontists evaluated and compared radiographs (weighted kappa values, κ = 0.8). The Mann-Whitney, t, chi-square, Fisher, and Bruner-Langer tests and analysis of variance-type statistics were used as appropriate. RESULTS: The recall rate was 100%. All teeth in the IBD patients and 81% in the control patients healed (P = .108). Initial healing was appreciable at 3 months in the IBD group and 6 months in the control group (P = .174). Overall healing was reached at 6 and 10.5 months in the IBD and control groups, respectively (P = .106). At any time of the experiment, teeth in the IBD patients showed a higher probability of healing (P < .05). Both groups exhibited a similar decrement of the periapical index (P = .291), more significant for the IBD at the 3-month follow-up (P < .05). The 2 BMs used showed a similar trend of healing (P = .628). CONCLUSIONS: The treatment of AP in patients taking BMs had no complications; furthermore, it was associated with faster healing than the controls. These results support the possible therapeutic aid of BMs in treating AP.

来源:J Endod,查看原文。版权归原作者所有。

引用

  1. Cotti E, Mezzena S, Schirru E, et al. Healing of Apical Periodontitis in Patients with Inflammatory Bowel Diseases and under Anti-tumor Necrosis Factor Alpha Therapy. J Endod. 2018. PMID: 30390972. doi:10.1016/j.joen.2018.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。